"There's always a story. It's all stories, really. The sun coming up every day is a story. Everything's got a story in it. Change the story, change the world." — Terry Pratchett
Every investment is a story, a narrative of progress and promise, ambition and anticipation. This is especially true in the world of leading-edge science-driven companies where success often hinges on the ability to tell a compelling tale. Unlike traditional business models that often generate quick returns, these ventures typically require significant time and funding before their pioneering products or solutions ever hit the market. In this field, the narrative woven around a venture is not a luxury, but a necessity.
It is important to understand that there's a longer game at play. Essentially, the narrative crafted today must be robust and convincing enough to be passed on and further elaborated by these initial investors to subsequent potential investors down the line.
Venture investments, particularly in the realm of biotechnology and other science-driven sectors, are often characterized by high capital requirements spread across various financing rounds. The capital-intensive nature of these ventures necessitates the continuous acquisition of new investors, each of whom requires persuasion and assurance of the venture's viability and promise. Hence, the original investor doesn't just need to be convinced about the investment's potential. They also need to become advocates for the venture, equipped with a compelling story that they can relay convincingly to others. Essentially, the initial investors play a crucial role as storytellers, carrying the investment narrative forward to subsequent rounds of financing.
This critical role of the initial investor highlights the utmost importance of crafting an engaging, persuasive, and robust narrative from the get-go. The investment story must be grounded in strong scientific rationale, showcasing a significant problem and a unique, viable solution. It should illuminate the competitive landscape and underline the venture's unique selling proposition. It must also resonate with future aspirations, highlighting the potential growth and long-term prospects of the venture.
The Importance of Story in Investment
The narrative of a leading-edge company is not just a marketing tool, it is an integral part of the venture itself. It acts as the blueprint of the journey that the company has embarked upon, illuminating the path from the initial idea to its potential realization. This narrative doesn't merely tell "what" the company does; it expresses "why" it does what it does and "how" it plans to accomplish its goals. It paints a picture of the problem at hand, articulates why it matters, and describes how the company's unique approach or technology provides an effective solution.
Importantly, a good story distinguishes a company from its competitors, carving out a niche that highlights its unique selling proposition. It underlines the novelty and the potential of the technology or science that the company employs, and positions it within the broader context of the field, reinforcing its relevance and promise.
As much as facts, figures, and data points are essential, investment decisions are also emotionally charged. No investor will ever make a decision because of a number: We need a story. A story stirs the imagination, inspires trust, and triggers an emotional connection. This is crucial, especially in the often-uncertain early stages of a venture, when the financial returns are yet to materialize, and it's the strength of the story that keeps investors engaged and committed. Several critical elements form the structure of a compelling investment story:
- Problem Identification: At the heart of every innovation lies a problem in dire need of a solution. The story of an investment should start with clearly identifying this problem. The issue at hand must be significant, relevant, and compelling enough to warrant the need for a solution. The problem's gravity provides a strong motivation for investors, inspiring them to contribute to a venture that aims to solve it.
- Unique Solution: Once the problem is established, the narrative should introduce the unique solution that the company brings to the table. This solution should be grounded in advanced scientific development and innovation, highlighting the company's unique capabilities and resources. The narrative should communicate how the proposed solution effectively addresses the identified problem and why it is better than existing solutions, if any.
High Activity in the Area: A crucial part of the investment narrative involves shedding light on the level of activity in the particular industry or sector. This includes the number of financing deals that are taking place, the volume of these transactions, and, most importantly, the frequency and size of liquidity events, exits, or transactions with pharmaceutical companies or Initial Public Offerings (IPOs).
High levels of activity often indicate a vibrant and growing market, one that holds substantial promise and potential for investors. Such activity also signifies the confidence of other investors in the sector, thereby offering some level of validation. It is important to explain the implications of these activities — for instance, large liquidity events signal profitable exit opportunities, and frequent deals might suggest a fast-paced, competitive environment. This element of the narrative helps investors understand the dynamism and potential profitability of the investment area.
People Behind the Idea — Scientific Stature: When considering an investment in a science-driven venture, it's crucial to assess the scientific stature of the team and those backing the idea. The creator of the science's importance in the field, their academic credentials, and previous achievements can have a significant impact on the viability and potential of the venture. The publication of research associated with the venture in reputable scientific journals enhances credibility and provides validation from the scientific community.
Additionally, the participation of experienced independent directors on the board signals faith in the venture's potential, offering further reassurance to investors. Furthermore, endorsement from key opinion leaders, respected individuals in the field, implies that the venture's science is promising and worth investing in, thereby boosting investor confidence and enhancing the compelling nature of the investment narrative.
Future Potential of the Field or Technology: A compelling story should resonate with the investors' aspirations for the future. Tying back to the "forest and the trees" concept, the narrative should demonstrate the investment's relevance to the future of the field, pointing out the trajectory it is expected to take.
A compelling story should spark enthusiasm and create a sense of anticipation about the company's potential for growth and success. This aspect of the narrative contributes to the sustainability of investor engagement and commitment.
Thus, the importance of story in investment is twofold. On the one hand, it provides the necessary context and clarity that helps potential investors understand the vision and potential of a venture. On the other, it serves as an emotional anchor, providing a sense of purpose and direction that can inspire trust and commitment.
An Amazing Truth
The dynamic nature of cutting-edge fields such as biotech, synthetic biology, AI, or any leading-edge space for that matter, is what makes them so incredibly fascinating. It's also what makes them challenging, and to succeed in these fields, one needs to be adaptable and forward-thinking.
As I reflect on my journey, one fact stands out starkly: The field evolves with staggering rapidity. It is a testament to this that even the companies in which I once saw immense potential and that yielded great success, I might not choose to invest in today.
If these same companies, which once were great winners for us, were to approach us now, they might not make it through to a second meeting. This is not because these companies have lost their value, nor does it undermine their past achievements. Instead, it underscores the accelerated pace at which the landscape is evolving and, consequently, our ever-evolving benchmarks for investment potential.
Like natural evolution, it's survival of the fittest. Companies that were once fit for the investment environment may not meet the evolved standards of today's context. This constant flux underscores the need for investors and entrepreneurs to continually update their strategies rather than resting on past laurels.
Another angle I want you to consider here is the role of serendipity and randomness in venture success. As much as we'd like to believe that success is purely a function of strategic decision-making and superior judgment, the reality is often far from it.
Sometimes, it's about being in the right place at the right time, spotting an opportunity that others missed, or simply riding a wave of favorable market conditions. Recognizing this aspect can make us more humble and open to diverse investment opportunities.
We, as investors, evolve with the landscape. Our understanding deepens, our perspectives widen, and our strategies refine. We learn from every decision, every investment, every success, and every setback. We are not the same investors we were 20 years ago, or even a year ago. And that's exactly how it should be.
In essence, past success does not guarantee future success in this rapidly evolving field. Being open to change, crafting good stories to tell other investors along the way, staying curious, and continually learning — these are the traits that will allow us to navigate the shifting landscape of leading-edge spaces. We need to keep our fingers on the pulse of change, to anticipate the direction of evolution, and to adapt accordingly. This is our pathway to continued success in a world where the only constant is change.
Excerpted from Fast Forward Thinking: 40 Rules for Entrepreneurs and Investors in Medical, Science, and Biotech (American Association for Physician Leadership, 2024).
